Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630370 · ClinicalTrials.gov registry record · Phase 2
A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome
A Phase 2 study, sponsored by Procter and Gamble.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00630370 is a Phase 2 study that was terminated before completion, run by Procter and Gamble. The registered enrollment target is 6 participants.
The verdict
NCT00630370, a Phase 2 study, was terminated before completion, sponsored by Procter and Gamble.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
To assess the efficacy of 3 oral dosing regimens of ATI 7505 compared to placebo in patients with PDS by comparing at the end of Day 42 the percentage of patients in each treatment group who have had adequate relief of postprandial distress syndrome symptoms on at least 50% of the treatment days.
Interventions
- DRUG Placebo
- DRUG 20 mg ATI 7505
- DRUG 40 mg ATI 7505
- DRUG 80 mg ATI 7505
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00630370
The ClinicalTrials.gov registry entry for NCT00630370 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Procter and Gamble, which has 70 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00630370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00630370 about?
NCT00630370 is a clinical study titled "A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome". To assess the efficacy of 3 oral dosing regimens of ATI 7505 compared to placebo in patients with PDS by comparing at the end of Day 42 the percentage of patients in each treatment group who have had adequate relief of postprandial distress syndrome symptoms on at least 50% of the treatment days.
What is the current status of trial NCT00630370?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2008-02. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00630370?
The interventions under investigation include: Placebo (DRUG), 20 mg ATI 7505 (DRUG), 40 mg ATI 7505 (DRUG), 80 mg ATI 7505 (DRUG).
Who is sponsoring clinical trial NCT00630370?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.